LON:RENE - ReNeuron Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 83.50 +2.00 (+2.45 %)
(As of 06/22/2018 04:00 PM ET)
Previous CloseGBX 83.50
Today's RangeGBX 80 - GBX 84.80
52-Week RangeGBX 1.37 - GBX 142.50
Volume21,144 shs
Average Volume28,700 shs
Market Capitalization£29.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group logoReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:RENE
CUSIPN/A
Phone+44-20-38198400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-39,870.83%
Return on Equity-39.23%
Return on Assets-34.91%

Miscellaneous

EmployeesN/A
Outstanding Shares3,160,000,000

ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) announced its earnings results on Thursday, December, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter. ReNeuron Group had a negative return on equity of 39.23% and a negative net margin of 39,870.83%. View ReNeuron Group's Earnings History.

What price target have analysts set for RENE?

1 analysts have issued 1 year price objectives for ReNeuron Group's shares. Their forecasts range from GBX 13 to GBX 13. On average, they anticipate ReNeuron Group's share price to reach GBX 13 in the next year. View Analyst Ratings for ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, Chief Exec. Officer and Director (Age 53)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 55)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 67)
  • Dr. Randolph Corteling, Head of Research
  • Ms. Sharon Grimster FSB, AFIChemE, BSc, DMS, VP of Devel. & GM of Wales (Age 59)

Has ReNeuron Group been receiving favorable news coverage?

Headlines about RENE stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ReNeuron Group earned a media sentiment score of 0.03 on Accern's scale. They also assigned news coverage about the company an impact score of 46.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 83.50.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £29.11 million.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (RENE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.